News
EUSA Pharma launches phase III COVID-19 study for siltuximab
UK-headquartered EUSA Pharma has enrolled the first patient in a phase III study of siltuximab in patients hospitalised with COVID-19.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
UK-headquartered EUSA Pharma has enrolled the first patient in a phase III study of siltuximab in patients hospitalised with COVID-19.